OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models
出版年份 2016 全文链接
标题
OTX015 (MK-8628), a novel BET inhibitor, displaysin vitroandin vivoantitumor effects alone and in combination with conventional therapies in glioblastoma models
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 9, Pages 2047-2055
出版商
Wiley
发表日期
2016-07-08
DOI
10.1002/ijc.30256
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
- (2015) A. Henssen et al. CLINICAL CANCER RESEARCH
- Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
- (2015) Elodie Odore et al. CLINICAL PHARMACOKINETICS
- BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
- (2015) Marie-Magdelaine Coudé et al. Oncotarget
- Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
- (2015) Harald Herrmann et al. Oncotarget
- Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples
- (2014) Elodie Odore et al. Analytical Methods
- Pathology of Gliomas and Developments in Molecular Testing
- (2014) V.P. Collins CLINICAL ONCOLOGY
- BET bromodomain proteins are required for glioblastoma cell proliferation
- (2014) Chiara Pastori et al. Epigenetics
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
- (2014) C Wong et al. Cell Death & Disease
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Developing epigenetic diagnostics and therapeutics for brain disorders
- (2013) Irfan A. Qureshi et al. TRENDS IN MOLECULAR MEDICINE
- BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
- (2012) C. J. Ott et al. BLOOD
- Small-Molecule Inhibition of BRDT for Male Contraception
- (2012) Martin M. Matzuk et al. CELL
- Down-regulation of NF-κB Transcriptional Activity in HIV-associated Kidney Disease by BRD4 Inhibition
- (2012) Guangtao Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adult glioblastoma multiforme survival in the temozolomide era: A population-based analysis of Surveillance, Epidemiology, and End Results registries
- (2011) Amy S. Darefsky et al. CANCER
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Bromodomains as therapeutic targets
- (2011) Susanne Muller et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Blood-brain barrier damage and brain penetration of antiepileptic drugs: Role of serum proteins and brain edema
- (2009) Nicola Marchi et al. EPILEPSIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now